ODs with a positive TPR conclusion, not subject to a conditional approval, and approved without requering a pass would be more likely to be reimbursed in Spain
Abstract Background The present study aims to assess clinical and regulatory variables that would influence pricing and reimbursement (P&R) decisions for Orphan Drugs (ODs) in Spain. ODs approved by the European Commission (EC) between 2006 and 2021 were classified according to their P&R status in S...
Spremljeno u:
| Glavni autori: | , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BMC
2023-01-01
|
| Serija: | Orphanet Journal of Rare Diseases |
| Teme: | |
| Online pristup: | https://doi.org/10.1186/s13023-022-02610-4 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|